NDLI: IFN- in the treatment of melanoma.

Please wait, while we are loading the content...

HLA-DM constrains epitope selection in the human CD4 T cell response to vaccinia virus by favoring the presentation of peptides with longer HLA-DM-mediated half-lives.

Mannan-binding lectin-associated serine protease (MASP)-1 is crucial for lectin pathway activation in human serum, whereas neither MASP-1 nor MASP-3 is required for alternative pathway function.

Increased memory differentiation is associated with decreased polyfunctionality for HIV but not for cytomegalovirus-specific CD8+ T cells.

B7x in the periphery abrogates pancreas specific damage mediated by self-reactive CD8 T cells

Inhibitors of DNA binding proteins restrict T cell potential by repressing Notch1 expression in Flt3-negative common lymphoid progenitors.

Role of macrophage migration inhibitory factor in the regulatory T cell response of tumor-bearing mice.

Genetic ablation of arginase 1 in macrophages and neutrophils enhances clearance of an arthritogenic alphavirus.

IFN- and lipopolysaccharide upregulate APOBEC3 mRNA through different signaling pathways.

Chronic beryllium disease, HLA-DPB1, and the DP peptide binding groove.

MicroRNAs control the maintenance of thymic epithelia and their competence for T lineage commitment and thymocyte selection.

Blockade of IL-10 signaling during bacillus Calmette-Guérin vaccination enhances and sustains Th1, Th17, and innate lymphoid IFN-Î³ and IL-17 responses and increases protection to Mycobacterium tuberculosis infection.

Dendritic cell-specific disruption of TGF-ß receptor II leads to altered regulatory T cell phenotype and spontaneous multiorgan autoimmunity.

CD11c+ cells are required for antigen-induced increase of mast cells in the lung.

IL-10-producing regulatory B cells in the pathogenesis of chronic hepatitis B virus infection.

Regulation of inflammatory response by 3-methyladenine involves the coordinative actions on Akt and glycogen synthase kinase 3ß rather than autophagy.

Extensive diversification of IgD-, IgY-, and truncated IgY(Î´Fc)-encoding genes in the red-eared turtle (Trachemys scripta elegans).

Autophagy regulates IL-23 secretion and innate T cell responses through effects on IL-1 secretion.

The importance of the Erk pathway in the development of linker for activation of T cells-mediated autoimmunity.

Cell-intrinsic abrogation of TGF-ß signaling delays but does not prevent dysfunction of self/tumor-specific CD8 T cells in a murine model of autochthonous prostate cancer.

Immunoproteasome subunit LMP7 deficiency and inhibition suppresses Th1 and Th17 but enhances regulatory T cell differentiation.

Protective immunity against pulmonary cryptococcosis is associated with STAT1-mediated classical macrophage activation.

ATP induces protein arginine deiminase 2-dependent citrullination in mast cells through the P2X7 purinergic receptor.

Receptor cross-talk spatially restricts p-ERK during TLR4 stimulation of autoreactive B cells.

Cutting edge: miR-223 and EBV miR-BART15 regulate the NLRP3 inflammasome and IL-1ß production.

NLRP3 inflammasome activity is negatively controlled by miR-223.

Cutting edge: NADPH oxidase modulates MHC class II antigen presentation by B cells.

Abelson tyrosine kinase controls phagosomal acidification required for killing of Mycobacterium tuberculosis in human macrophages.

Scavenger receptor in fish is a lipopolysaccharide recognition molecule involved in negative regulation of NF-κB activation by competing with TNF receptor-associated factor 2 recruitment into the TNF- signaling pathway.

Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection.

Prevention of virus-induced type 1 diabetes with antibiotic therapy.

Foxp3 expression is required for the induction of therapeutic tissue tolerance.

The thymic niche does not limit development of the naturally diverse population of mouse regulatory T lymphocytes.

IFN- in the treatment of melanoma.

Year: 2012 Volume: 189 Issue: 7

Year: 2012 Volume: 189 Issue: 6

Year: 2012 Volume: 189 Issue: 5

Year: 2012 Volume: 189 Issue: 4

Year: 2012 Volume: 189 Issue: 3

Year: 2012 Volume: 189 Issue: 2

Year: 2012 Volume: 189 Issue: 1

Year: 2012 Volume: 188

Year: 2011 Volume: 187

Year: 2011 Volume: 186

Year: 2010 Volume: 185

Year: 2010 Volume: 184

Year: 2009 Volume: 183

Year: 2009 Volume: 182

Year: 2008 Volume: 181

IFN- in the treatment of melanoma.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Gogas, Helen Tarhini, Ahmad A. Kirkwood, John M.
Spatial Coverage	United States
Description	Country affiliation: United States Author Affiliation: Tarhini AA ( Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA. tarhiniaa@upmc.edu)
Abstract	Among the IFNs, IFN- 2 has been the most broadly evaluated clinically. At the molecular level, IFN- has multiple effects in a variety of malignancies that range from antiangiogenic to potent immunoregulatory, differentiation-inducing, antiproliferative, and proapoptotic effects. A multitude of IFN- 2 regimens that may be classified as low dose, intermediate dose, and high dose have been evaluated as adjuvant therapy in melanoma. A durable impact on both relapse-free and overall survival was seen only with the regimen utilizing high-dose IFN- 2b tested in the Eastern Cooperative Oncology Group and intergroup trials E1684, E1690, and E1694 as adjuvant therapy for high-risk surgically resected melanoma (stage IIB or III). Adjuvant pegylated IFN- 2b has also been evaluated at maximally tolerable doses compared with the observation group in the European Organization for Research and Treatment of Cancer trial 18991 and has shown relapse-free survival benefits in patients with microscopic nodal disease.
ISSN	00221767
e-ISSN	15506606
DOI	10.4049/jimmunol.1290060
Journal	The Journal of Immunology
Issue Number	8
Volume Number	189
Language	English
Publisher	The American Association of Immunologists
Publisher Date	2012-10-15
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Interferon-alpha Therapeutic Use Melanoma Immunology Therapy Adjuvants, Immunologic Clinical Trials, Phase I As Topic Clinical Trials, Phase Ii As Topic Dose-response Relationship, Immunologic Antagonists & Inhibitors Meta-analysis As Topic Tumor Escape United States Food And Drug Administration Discipline Immunology
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Secukinumab (AIN457) for the treatment of psoriasis.

Biological agents for controlling excessive scarring.

Ruxolitinib for the treatment of patients with polycythemia vera.

Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis.

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

Summary of the International Multicenter Prospective Angioedema C1-inhibitor Trials 1 and 2 (IMPACT1 and 2).

The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death.

Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.

Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.

IFN- in the treatment of melanoma.

Similar Documents

Secukinumab (AIN457) for the treatment of psoriasis.

Biological agents for controlling excessive scarring.

Ruxolitinib for the treatment of patients with polycythemia vera.

Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasis.

Immunogenicity of Anti-TNF-alpha agents in autoimmune diseases.

Summary of the International Multicenter Prospective Angioedema C1-inhibitor Trials 1 and 2 (IMPACT1 and 2).

The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death.

Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials.

Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.

IFN- in the treatment of melanoma.